Abstract:Background/Synopsis Multifactorial chylomicronemia syndrome (MCS), also known as type V hyperlipoproteinemia, is a rare polygenic disorder characterized by severe hypertriglyceridemia. It is triggered by uncontrolled diabetes mellitus (DM), obesity, metabolic syndrome, and certain medications. It is not known whether hypertriglyceridemia associated with MCS accelerates atherosclerotic cardiovascular disease (ASCVD). Objective/Purpose To speculate the relationship between ASCVD in a patient with hypertriglyceridemia caused by MCS, uncontrolled DM, and polymorphic APOA5, APOE2/4, LMF1 and LP(a) intron mutations. Methods We present a 60-year-old male with PMH of severe hypertriglyceridemia (highest 6000mg/dL) with acute pancreatitis at age 40, CAD s/p CABG at age 50, PAD s/p bypass at age 57, HTN, mixed hyperlipidemia, uncontrolled DM, and family history of premature ASCVD. He was subsequently followed at the advanced lipid clinic where his medications included rosuvastatin, ezetimibe, evolocumab, fenofibrate, and icosapent ethyl. He underwent advanced genetic testing with GBinsight. Results GBinsight identified various polymorphic genes causing hypertriglyceridemia as follows: APOA5 - c.*158C>T(rs2266788) - This variant is found in ∼10% of the global population and has been associated with hypertriglyceridemia by multiple genome-wide association studies. APOA5 - c.457G>A(p.Val153Met)(rs3135507) - This variant is found in ∼5-10% of the global population and has been associated with modest hypertriglyceridemia and lower HDL-C in the UKBiobank cohort. APOE2 - This allele has been associated with a reduction of the major lipolytic enzyme, lipoprotein lipase (LPL) activity, causing modest hypertriglyceridemia. LMF1 - p.Arg354Trp(rs143076454) - This variant is found in ∼2% of the global population, and has been associated with a reduction of LPL activity causing modest hypertriglyceridemia. GBinsight identified various pathogenic genes causing elevated Lp(a) as follows: LPA - Heterozygous for intron c.3947+467T>C(rs10455872) - This variant serves a genetic proxy for short isoforms and is strongly associated with increased Lp(a), total and LDL-cholesterol levels, and increased ASCVD risk. APOE4 - This allele is associated with increased Lp(a) levels. Conclusions We speculate that the combination of these polymorphisms works together to increase risk of severe hypertriglyceridemia, also known as MCS. Several smaller studies have suggested MCS is caused by either of the two major mechanisms: (1) some combination of minor genetic polymorphisms, or (2) presence of a single genetic mutation in one of the five genes regulating triglyceride metabolism including LPL, APOC2, APOA5, GPHIBP1, and LMF1. We postulate acceleration of ASCVD in our patient with MCS was multifactorial, including deposition of atherogenic triglyceride rich lipoproteins within blood vessels, in addition to the independent risk factor of elevated Lp(a). Furthermore, he had poorly controlled DM and insulin resistance owing to the increased circulating triglycerides, which further increased endothelial lining damage and accelerated ASCVD.

Comparison of patients with familial chylomicronemia syndrome and multifactorial chylomicronemia syndrome

Ethnic Diversity and Distinctive Features of Familial Versus Multifactorial Chylomicronemia Syndrome: Insights From the UK FCS National Registry

The Evolving Story of Multifactorial Chylomicronemia Syndrome

Identification of a Compound Heterozygous LMF1 Variants in a Patient with Severe Hypertriglyceridemia – Case Report and Literature Review

Development of a Clinical Diagnostic Score for Familial Chylomicronemia Syndrome (FCS)

Severe Hypertriglyceridemia in Patients with Type 2 Diabetes Mellitus Participating in the AMD Annals Initiative

Analysis of a Chinese Pedigree With Familial Chylomicronemia Syndrome Reveals Two Novel LPL Mutations by Whole-Exome Sequencing.

Clinical Profile, Genetic Spectrum and Therapy Evaluation of 19 Chinese Pediatric Patients with Lipoprotein Lipase Deficiency

Significant Quality of Life Improvement Observed in a Patient With FCS Associated With a Marked Reduction in Triglycerides

Familial chylomicronemia syndrome: case reports of siblings with deletions of the GPIHBP1 gene

Pancreatic and cardiometabolic complications of severe hypertriglyceridaemia

Accelerated Atherosclerosis in a Patient With Multifactorial Chylomicronemia Syndrome (MCS), Elevated Lp(a), APOE2/4 Genotype and Diabetes Mellitus.

Abstract 10357: ARO-APOC3, an Investigational RNAi Therapeutic, Shows Similar Efficacy and Safety in Genetically Confirmed FCS and Non-FCS Participants with Severe Hypertriglyceridemia

High hsCRP concentration is associated with acute pancreatitis in multifactorial chylomicronemia syndrome

Identification and functional analysis of novel homozygous LMF1 variants in severe hypertriglyceridemia

Plasma Exchange Therapy for Familial Chylomicronemia Syndrome in Infant: A Case Report

Familial hypercholesterolaemia with high triglycerides: A diagnostic challenge

Lipidomic profiling in patients with familial hypercholesterolemia: Abnormalities in glycerolipids and oxysterols

Long-Term Clinical Outcomes and Management of Hypertriglyceridemia in Children with Apo CII Deficiency

Molecular mechanisms, prevalence, and molecular methods for familial combined hyperlipidemia disease: A review

Characterization of lipoprotein profiles in patients with hypertriglyceridemic Fredrickson-Levy and Lees dyslipidemia phenotypes: the Very Large Database of Lipids Studies 6 and 7